A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

• Status: Completed
• Trial end date: 2016-10-14

Summary

The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent acute coronary syndrome (ACS: including ST segment elevation myocardial infarction [STEMI] and non-ST-segment elevation acute coronary syndrome [NSTE-ACS]).

• Phase: Phase 2

Details

• Lead Sponsor: Janssen Research & Development, LLC
• Collaborators: Bayer; Duke Clinical Research Institute; Harvard Medical School; Harvard Medical School (HMS and HSDM)
• Treatments: Aspirin; Clopidogrel; Rivaroxaban; Ticagrelor; Ticlopidine